Bemiparin

Therapeutic indications

Bemiparin is indicated for:

Prevention of thromboembolic disease in orthopaedic surgery

Population group: only adults (18 years old or older)

Prevention of thromboembolic disease in patients undergoing orthopaedic surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of clotting in the extracorporeal circuit during haemodialysis

Population group: only adults (18 years old or older)

at least one of
Anticoagulant prophylaxis
Prevention of deep vein thrombosis
and additionally at least one of
Extracorporeal circulation procedure
Hemodialysis procedure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Deep vein thrombosis

Population group: only adults (18 years old or older)

The treatment of established deep vein thrombosis, with or without pulmonary embolism, during the acute phase.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Bemiparin is contraindicated in the following cases:

Locoregional anaesthesia

Regional anesthesia

Operations on the central nervous system, eyes and ears

at least one of
Operation on brain
Procedure on spinal cord
Surgical procedure on eye region
Operation on the ear

Heparin induced thrombocytopenia

Heparin-induced thrombocytopenia

Haemorrhage

Bleeding

Severe impairment of liver or pancreatic function

at least one of
Hepatic failure stage IV
Abnormal pancreatic function

Disseminated intravascular coagulation (DIC)

Disseminated intravascular coagulation

Acute bacterial endocarditis, slow endocarditis

at least one of
Acute bacterial endocarditis
Subacute bacterial endocarditis

High risk of bleeding, peptic ulcer, haemorrhagic stroke, cerebral aneurysm or cerebral neoplasms

at least one of
High risk of hemorrhage
Peptic ulcer
Cerebral hemorrhage
Cerebral aneurysm
Intracranial tumour

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: ZIBOR 2.500 IU Solution for injection
Summary of Product Characteristics (SPC) 2021: ZIBOR 3.500 IU Solution for injection
Summary of Product Characteristics (SPC) 2021: ZIBOR 25.000 IU Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈